Midwest Clinical Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$413,441	24
2024	Research	$821,032	24
2023	Research	$442,792	14
2022	Research	$908,614	12
2021	Research	$1,237,256	10
2020	Research	$129,564	21
2019	Research	$465,858	12

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $2,909,854 34 payments
AstraZeneca UK Limited $823,732 7 payments
GlaxoSmithKline, LLC. $462,636 55 payments
Novartis Pharmaceuticals Corporation $206,829 8 payments
Indivior Inc. $15,506 13 payments

Studies the money was for Research payments · program years 2019–2025

A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $2,144,461 5 payments
A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease $309,403 3 payments
A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) $270,195 5 payments
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $260,890 10 payments
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $219,903 4 payments
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Para $180,470 26 payments
A Phase IV, 12 Week, Randomised, Double Blind Study to Compare Single $156,825 8 payments
A Phase II Randomized Openlabel Multicenter Doseranging Study in Adults and Pediatric Individuals 2265 12 years of Age to Assess the Safety Immunogenicity Pharmacokinetics and Pharmacodynamics of AZD7442 a Combination Product of Two Monoclonal Antibodies Tixagevimab and Cilgavimab for Pre-exposure Prophylaxis of COVID19 $155,125 3 payments
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL $125,341 1 payment
A Multi Center Randomized Double Blind Active and Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis $108,539 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.